 Genprex, Inc. NASDAQ:GNPX said it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of 6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules to raise 25 million. The clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes said no warrants will be issued in connection with the transaction. 